One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C

por Xu, Jing-Hang, Wang, Sa, Zhang, Da-Zhi, Yu, Yan-Yan, Si, Chong-Wen, Zeng, Zheng, Xu, Zhong-Nan, Li, Jun, Mao, Qing, Tang, Hong, Sheng, Ji-Fang, Chen, Xin-Yue, Ning, Qin, Shi, Guang-Feng, Xie, Qing, Zhang, Xi-Quan, Dai, Jun
Publicado 2022

240‐week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C

por Xu, Jing‐Hang, Fan, Ya‐Nan, Yu, Yan‐Yan, Si, Chong‐Wen, Zeng, Zheng, Xu, Zhong‐Nan, Li, Jun, Mao, Qing, Zhang, Da‐Zhi, Tang, Hong, Sheng, Ji‐Fang, Chen, Xin‐Yue, Ning, Qin, Shi, Guang‐Feng, Xie, Qing, Zhang, Xi‐Quan, Dai, Jun
Publicado 2022

A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) versus Viread for the treatment of chronic hepatitis B: First-s...

por Liang, Rong-Yue, Xu, Jing-Hang, Si, Chong-Wen, Wang, Sa, Shang, Jia, Yu, Zu-Jiang, Mao, Qing, Xie, Qing, Zhao, Wei, Li, Jun, Gao, Zhi-Liang, Wu, Shan-Ming, Tang, Hong, Cheng, Jun, Chen, Xin-Yue, Zhang, Wen-Hong, Wang, Hao, Xu, Zhong-Nan, Wang, Ling, Dai, Jun, Yu, Yan-Yan
Publicado 2019

Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96 weeks

por Chen, Xiao-Fan, Fan, Ya-Nan, Si, Chong-Wen, Yu, Yan-Yan, Shang, Jia, Yu, Zu-Jiang, Mao, Qing, Xie, Qing, Zhao, Wei, Li, Jun, Gao, Zhi-Liang, Wu, Shan-Ming, Tang, Hong, Cheng, Jun, Chen, Xin-Yue, Zhang, Wen-Hong, Wang, Hao, Xu, Zhong-Nan, Wang, Ling, Dai, Jun, Xu, Jing-Hang
Publicado 2021